The Enduring Challenge of Powering Cardiac Implants

Cardiac implantable electronic devices (CIEDs) have fundamentally altered the management of bradyarrhythmias, heart failure, and sudden cardiac death risk. According to the American Heart Association, hundreds of thousands of pacemakers and defibrillators are implanted globally each year. Despite remarkable progress in device miniaturization and therapeutic functionality, the clinical community remains constrained by a single, persistent limitation: the battery. Modern lithium-iodine batteries provide a reliable service life of roughly 5 to 10 years, after which the entire generator must be replaced through a surgical procedure. For a growing population of patients who receive these devices at a younger age, this guarantees multiple invasive interventions over a lifetime. Each “box change” carries non-trivial risks, including pocket infections, hematomas, and lead damage. Studies published in major cardiology journals demonstrate that the morbidity associated with generator replacement is significant, particularly in elderly or frail patients. Eliminating the battery would change the fundamental calculus of long-term device therapy.

Wireless Energy Transfer Through Ultrasound

Ultrasound-mediated wireless power transfer (WPT) offers a scientifically robust alternative to electrochemical energy storage. The core principle relies on the transmission of high-frequency acoustic waves (typically in the 0.5 to 10 MHz range) from an external transducer placed on the skin surface. These mechanical waves propagate efficiently through soft tissue with relatively low attenuation compared to electromagnetic fields at similar frequencies. A miniaturized piezoelectric transducer integrated into the implant captures these acoustic waves. The mechanical stress induced by the pressure wave generates an electrical charge inside the transducer material via the direct piezoelectric effect. This alternating current (AC) is then rectified, filtered, and regulated to power the device’s microelectronics or to charge a small integrated capacitor. Because ultrasound energy can be tightly focused using phased array technology, it is uniquely suited for delivering power to small implants located deep within the thoracic cavity, regardless of the device's orientation relative to the skin.

Piezoelectric Materials as Power Receivers

The efficiency of the energy conversion depends heavily on the material properties of the receiving transducer. Traditional lead zirconate titanate (PZT) ceramics have been the standard for decades due to their high electromechanical coupling. However, advances in single-crystal relaxor ferroelectrics, such as PMN-PT (lead magnesium niobate-lead titanate), have dramatically improved the power density that can be achieved from devices sized just a few millimeters in diameter. These materials exhibit higher coupling coefficients and lower dielectric losses, enabling viable power capture even at depths greater than 10 centimeters. Ongoing research focuses on integrating these advanced materials into biocompatible, hermetically sealed packages that can withstand the corrosive physiological environment for decades.

Comparative Advantages Over Conventional Power Systems

Replacing a bulky battery with an ultrasound receiver provides cascading benefits that extend well beyond simply limiting the number of surgeries. It opens the door to a complete rethink of implant architecture, patient management, and healthcare economics.

Eliminating Generator Replacement Procedures

The most immediate and impactful benefit is the avoidance of repeat surgery. For patients who are pacemaker-dependent, eliminating the 5-to-10-year replacement cycle reduces the cumulative lifetime risk of major complications, including infection of the device pocket (which often requires extraction of the entire system) and venous occlusion or damage from repeated transvenous lead revisions. For younger patients—such as those with congenital complete heart block—this benefit is particularly striking, potentially reducing the number of required cardiac surgeries from eight or ten to one or two over an 80-year lifespan.

Enabling Dramatic Device Miniaturization

Batteries occupy roughly 50% to 70% of the internal volume of a current-generation pacemaker. Unshackling device design from the battery allows engineers to focus on extreme miniaturization. Without a battery, the implantable component can shrink to the size of a large vitamin capsule. This facilitates entirely new implantation methods, such as fully injectable or catheter-deployed devices. Smaller implants also cause less tissue disruption at the implantation site, reduce the visible cosmetic bulge under the skin, and may lower the risk of chronic discomfort and device erosion.

Long-Term Economic Efficiency for Health Systems

While the upfront acquisition cost of an ultrasound-based system (including the external wearable transmitter) is likely higher, the lifetime cost profile is highly favorable. Each avoided surgical re-intervention saves the healthcare system thousands of dollars in operating room time, anesthesia, hospital stay, and follow-up care. When factoring in the cost of treating a single major device infection—often exceeding $50,000—the economic argument for a permanent, battery-free system becomes compelling. Health systems managing large cohorts of device-dependent patients could realize substantial net savings over a 10- to 20-year horizon.

Critical Safety and Technical Hurdles

Despite significant preclinical promise, the translation of ultrasound-powered CIEDs into routine clinical practice depends on solving several well-defined safety and engineering challenges. Oversight from bodies such as the FDA and the International Electrotechnical Commission (IEC) demands rigorous proof of safety across a wide range of operating conditions.

Managing Thermal Bioeffects

Focused ultrasound necessarily deposits energy into the tissue through which it passes. The primary safety concern is resistive heating of bone or soft tissue. The IEC 60601-2-5 standard provides strict temperature rise limits (typically less than 2°C) for diagnostic and therapeutic ultrasound. Imaging systems operating at diagnostic power levels pose minimal risk, but power delivery systems must manage significantly higher energy densities. Modern designs mitigate this risk by using low duty cycles, spreading the acoustic beam across a large aperture, and incorporating real-time thermal sensing or tissue models. Active beam-shaping techniques, where a large array of transducer elements is used to distribute the energy, help keep peak temperature rises well within the established safety margins.

Acoustic Cavitation and Mechanical Effects

At high acoustic intensities, ultrasound can induce mechanical cavitation—the formation and collapse of gas bubbles in the tissue fluids. This can cause localized mechanical damage. The Mechanical Index (MI) is a standard metric used to gate the risk of cavitation, with regulatory limits typically set at an MI of 1.9 for non-ophthalmic applications. Cardiac implant powering systems are generally designed to operate at frequencies and intensities where the MI remains well below this threshold, relying on continuous-wave or long-pulse sequences that favor thermal transfer over mechanical cavitation.

One of the most significant technical hurdles is maintaining a reliable acoustic link between the external transmitter and the moving internal receiver. The heart is in constant motion, and a patient’s posture changes throughout the day. Misalignment can cause a drop in received power, potentially compromising device function. Closed-loop adaptive beamforming is the leading strategy to address this. Miniature pilot signals from the implant allows the external array to continuously steer the acoustic focus, much like a laser-guided tracking system. This requires sophisticated integrated circuits within the implant and powerful digital signal processing in the external unit.

Regulatory Pathways and Clinical Translation

Moving from benchtop prototypes to approved medical devices requires a structured regulatory pathway. The FDA has established clear frameworks for wireless medical devices, but ultrasound-powered CIEDs represent a unique convergence of energy delivery and life-sustaining therapy. Preclinical evaluation will require comprehensive large animal studies to validate long-term safety, efficacy, and reliability. First-in-human studies will likely begin with temporary pacing applications, followed by permanent implantation in carefully selected patient cohorts. Collaboration with notified bodies and regulatory agencies early in the design process is essential to align on endpoint definitions and testing standards.

Current Research Landscape and Breakthroughs

The academic and industrial interest in ultrasound powering for medical implants has intensified sharply in the last five years. Groups at Stanford University and the University of Washington have demonstrated ultrasound-powered neural stimulators operating in the brain and spinal cord. More directly relevant to cardiology, preclinical studies published in high-impact journals have shown that ultrasound energy can reliably and safely power a leadless pacemaker in large animal models, achieving consistent capture and rate response for extended periods without battery depletion. These studies often utilize external arrays worn as a patch or belt, which provide the acoustic energy while simultaneously receiving telemetry data from the implant. The convergence of advanced beamforming, high-efficiency piezoelectrics, and ultra-low-power microelectronics has moved this technology from theoretical to demonstrably feasible.

Future Directions: Leadless Systems and Broader Applications

The ultimate expression of this technology is a fully leadless, battery-free cardiac implant. Current leadless pacemakers (e.g., Micra, Aveir) are limited by the physical size of their batteries, which determines both their longevity and the practical feasibility of retrieval at end of life. Ultrasound powering could allow these devices to become permanent fixtures with no functional expiration, eliminating the need for retrieval procedures. Researchers are also investigating whether the power levels achievable via ultrasound are sufficient for higher-energy applications such as subcutaneous defibrillation or cardiac resynchronization therapy. If successful, ultrasound powering could underpin an entire ecosystem of miniaturized, permanently implanted cardiac sensors and therapeutic devices, transforming the standard of care.

Potential for Multi-Organ Sensor Networks

Beyond the heart, ultrasound powering and communication can enable a network of distributed physiological sensors. Tiny, battery-free implants could be placed in the vasculature, the brain, or the spinal column to monitor pressure, temperature, or chemical biomarkers. These sensors would communicate via the same acoustic link, providing clinicians with a continuous stream of data without the need for leads or bulky implanted telemetry units. The cardiac implant serves as the logical first platform, given the high clinical need and well-established infrastructure for device-based care, but the foundational technology is broadly adaptable.

Conclusion: A Path Toward Durable Cardiac Therapy

Ultrasound-powered cardiac implants address the most persistent vulnerability in modern cardiac electrophysiology: the finite lifespan of the battery. By decoupling the energy supply from the implant’s structural volume, this approach offers a clear trajectory toward devices that can function for the entirety of a patient’s life without surgical revision. The clinical benefits—fewer operations, reduced infection risk, smaller implants, and lower long-term costs—are substantial. While the technical hurdles related to thermal safety, beam tracking, and regulatory approval are real, the research community has demonstrated that they are surmountable. The next decade will likely see the first human trials of permanent, battery-free pacing, marking a significant evolution in the management of cardiovascular disease and setting the stage for a new generation of truly long-term, minimally invasive implantable therapies.